1. Home
  2. PACK vs ATXS Comparison

PACK vs ATXS Comparison

Compare PACK & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PACK
  • ATXS
  • Stock Information
  • Founded
  • PACK 1972
  • ATXS 2008
  • Country
  • PACK United States
  • ATXS United States
  • Employees
  • PACK N/A
  • ATXS N/A
  • Industry
  • PACK Containers/Packaging
  • ATXS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PACK Consumer Discretionary
  • ATXS Health Care
  • Exchange
  • PACK Nasdaq
  • ATXS Nasdaq
  • Market Cap
  • PACK 445.5M
  • ATXS 424.4M
  • IPO Year
  • PACK N/A
  • ATXS 2015
  • Fundamental
  • Price
  • PACK $4.64
  • ATXS $7.52
  • Analyst Decision
  • PACK Buy
  • ATXS Buy
  • Analyst Count
  • PACK 3
  • ATXS 6
  • Target Price
  • PACK $7.17
  • ATXS $32.00
  • AVG Volume (30 Days)
  • PACK 1.3M
  • ATXS 315.6K
  • Earning Date
  • PACK 10-30-2025
  • ATXS 11-12-2025
  • Dividend Yield
  • PACK N/A
  • ATXS N/A
  • EPS Growth
  • PACK N/A
  • ATXS N/A
  • EPS
  • PACK N/A
  • ATXS N/A
  • Revenue
  • PACK $380,700,000.00
  • ATXS N/A
  • Revenue This Year
  • PACK $10.14
  • ATXS N/A
  • Revenue Next Year
  • PACK $7.92
  • ATXS N/A
  • P/E Ratio
  • PACK N/A
  • ATXS N/A
  • Revenue Growth
  • PACK 10.38
  • ATXS N/A
  • 52 Week Low
  • PACK $2.91
  • ATXS $3.56
  • 52 Week High
  • PACK $8.70
  • ATXS $12.92
  • Technical
  • Relative Strength Index (RSI)
  • PACK 49.16
  • ATXS 57.46
  • Support Level
  • PACK $4.56
  • ATXS $6.99
  • Resistance Level
  • PACK $5.25
  • ATXS $7.94
  • Average True Range (ATR)
  • PACK 0.26
  • ATXS 0.47
  • MACD
  • PACK -0.08
  • ATXS 0.04
  • Stochastic Oscillator
  • PACK 5.58
  • ATXS 69.92

About PACK Ranpak Holdings Corp

Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. Geographically, it derives a majority of its revenue from Europe/Asia. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.

About ATXS Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Share on Social Networks: